Genetic interpretation and clinical translation of minor genes related to Brugada syndrome.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
06 2019
Historique:
received: 02 12 2018
revised: 13 02 2019
accepted: 14 02 2019
pubmed: 2 3 2019
medline: 31 3 2020
entrez: 2 3 2019
Statut: ppublish

Résumé

Brugada syndrome (BrS) is an inherited arrhythmogenic disease associated with sudden cardiac death. The main gene is SCN5A. Additional variants in 42 other genes have been reported as deleterious, although these variants have not yet received comprehensive pathogenic analysis. Our aim was to clarify the role of all currently reported variants in minor genes associated with BrS. We performed a comprehensive analysis according to the American College of Medical Genetics and Genomics guidelines of published clinical and basic data on all genes (other than SCN5A) related to BrS. Our results identified 133 rare variants potentially associated with BrS. After applying current recommendations, only six variants (4.51%) show a conclusive pathogenic role. All definitively pathogenic variants were located in four genes encoding sodium channels or related proteins: SLMAP, SEMA3A, SCNN1A, and SCN2B. In total, 33.83% of variants in 19 additional genes were potentially pathogenic. Beyond SCN5A, we conclude definitive pathogenic variants associated with BrS in four minor genes. The current list of genes associated with BrS, therefore, should include SCN5A, SLMAP, SEMA3A, SCNN1A, and SCN2B. Comprehensive genetic interpretation and careful clinical translation should be done for all variants currently classified as potentially deleterious for BrS.

Identifiants

pubmed: 30821013
doi: 10.1002/humu.23730
doi:

Substances chimiques

Epithelial Sodium Channels 0
Membrane Proteins 0
NAV1.5 Voltage-Gated Sodium Channel 0
SCN2B protein, human 0
SCN5A protein, human 0
SCNN1A protein, human 0
SEMA3A protein, human 0
SLMAP protein, human 0
Semaphorin-3A 0
Voltage-Gated Sodium Channel beta-2 Subunit 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

749-764

Subventions

Organisme : Instituto de Salud Carlos III
Pays : International
Organisme : FUNDACIO Daniel Bravo Andreu
ID : FDBA
Pays : International
Organisme : Obra Social "La Caixa Foundation"
ID : 100010434
Pays : International
Organisme : Fondo Investigacion Sanitaria
ID : PI14/01773
Pays : International
Organisme : Fondo Investigacion Sanitaria
ID : PI17/01690
Pays : International
Organisme : Fondo Investigacion Sanitaria
ID : FIS PI16/01203
Pays : International
Organisme : Fundació Daniel Bravo Andreu
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Oscar Campuzano (O)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Medical Science Department, School of Medicine, University of Girona, Girona, Spain.

Georgia Sarquella-Brugada (G)

Medical Science Department, School of Medicine, University of Girona, Girona, Spain.
Arrhythmias Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.

Anna Fernandez-Falgueras (A)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Sergi Cesar (S)

Arrhythmias Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.

Monica Coll (M)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Jesus Mates (J)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Elena Arbelo (E)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Cardiology Service, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
IDIBAPS, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Alexandra Perez-Serra (A)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Bernat Del Olmo (B)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Paloma Jordá (P)

Cardiology Service, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
IDIBAPS, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Victoria Fiol (V)

Arrhythmias Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.

Anna Iglesias (A)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Marta Puigmulé (M)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Laura Lopez (L)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Ferran Pico (F)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.

Josep Brugada (J)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Arrhythmias Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Cardiology Service, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
IDIBAPS, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Ramon Brugada (R)

Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona, University of Girona, Girona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Medical Science Department, School of Medicine, University of Girona, Girona, Spain.
Cardiology Service, Hospital Josep Trueta, University of Girona, Girona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH